Vir and Gilead, two of the biggest names in the hunt for an HBV cure, team up for com­bi­na­tion tri­al

In De­cem­ber, Gilead closed out a year-long spend­ing spree on can­cer drugs by clos­ing a deal much clos­er to their roots: a $1.7 bil­lion deal for a Ger­man biotech fo­cused on he­pati­tis delta virus. It was a bet on a drug they’d watched for years and a sig­nal, Gilead vi­rol­o­gy chief Di­ana Brainard said, that al­though they’ve spent bil­lions on on­col­o­gy, they’re not leav­ing the field that turned them in­to a be­he­moth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER